Literature DB >> 33988235

Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis.

Rahul S Dalal1, Jennifer Mitri1, Hannah Goodrick1, Jessica R Allegretti1.   

Abstract

Entities:  

Keywords:  biologic therapy; clinical remission; comparative effectiveness; inflammatory bowel disease; ulcerative colitis

Mesh：

Substances：

Year:  2021        PMID： 33988235      PMCID： PMC8522788          DOI： 10.1093/ibd/izab097

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  6 in total

1.  Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Authors:  Bruce E Sands; William J Sandborn; Remo Panaccione; Christopher D O'Brien; Hongyan Zhang; Jewel Johanns; Omoniyi J Adedokun; Katherine Li; Laurent Peyrin-Biroulet; Gert Van Assche; Silvio Danese; Stephan Targan; Maria T Abreu; Tadakazu Hisamatsu; Philippe Szapary; Colleen Marano
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245

2.  Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Authors:  Bruce E Sands; Laurent Peyrin-Biroulet; Edward V Loftus; Silvio Danese; Jean-Frédéric Colombel; Murat Törüner; Laimas Jonaitis; Brihad Abhyankar; Jingjing Chen; Raquel Rogers; Richard A Lirio; Jeffrey D Bornstein; Stefan Schreiber
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245

3.  Reducing bias using propensity score matching.

Authors:  Charity J Morgan
Journal:  J Nucl Cardiol       Date:  2017-08-03       Impact factor: 5.952

4.  Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

Authors:  William J Sandborn; Chinyu Su; Bruce E Sands; Geert R D'Haens; Séverine Vermeire; Stefan Schreiber; Silvio Danese; Brian G Feagan; Walter Reinisch; Wojciech Niezychowski; Gary Friedman; Nervin Lawendy; Dahong Yu; Deborah Woodworth; Arnab Mukherjee; Haiying Zhang; Paul Healey; Julian Panés
Journal:  N Engl J Med       Date:  2017-05-04       Impact factor: 91.245

Review 5.  First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.

Authors:  Siddharth Singh; Mohammad Hassan Murad; Mathurin Fumery; Parambir S Dulai; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2020-01-13       Impact factor: 11.382

6.  Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.

Authors:  Remo Panaccione; Silvio Danese; William J Sandborn; Christopher D O'Brien; Yiying Zhou; Hongyan Zhang; Omoniyi J Adedokun; Ilia Tikhonov; Stephan Targan; Maria T Abreu; Tadakazu Hisamatsu; Ellen J Scherl; Rupert W Leong; David S Rowbotham; Ramesh P Arasaradnam; Bruce E Sands; Colleen Marano
Journal:  Aliment Pharmacol Ther       Date:  2020-10-21       Impact factor: 8.171
  6 in total
  1 in total

Review 1.  Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab.

Authors:  Daniela Pugliese; Giuseppe Privitera; Marcello Fiorani; Laura Parisio; Valentin Calvez; Alfredo Papa; Antonio Gasbarrini; Alessandro Armuzzi
Journal:  Therap Adv Gastroenterol       Date:  2022-06-13       Impact factor: 4.802
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.